A Randomized, Partially-Blinded, Placebo-Controlled, Two-Way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model.

Trial Profile

A Randomized, Partially-Blinded, Placebo-Controlled, Two-Way Crossover, Proof of Concept Study to Compare the Relative Efficacy of CRTh2 Receptor Antagonist, QAV680 Against Placebo in the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber (EEC) Model.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2010

At a glance

  • Drugs Mometasone; QAV 680
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top